X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs SUN PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA SUN PHARMA CIPLA/
SUN PHARMA
 
P/E (TTM) x 39.3 35.3 111.2% View Chart
P/BV x 3.6 3.8 95.8% View Chart
Dividend Yield % 0.5 0.3 140.0%  

Financials

 CIPLA   SUN PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-18
SUN PHARMA
Mar-18
CIPLA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs663701 94.6%   
Low Rs479433 110.6%   
Sales per share (Unadj.) Rs189.0110.4 171.2%  
Earnings per share (Unadj.) Rs17.611.0 160.3%  
Cash flow per share (Unadj.) Rs34.017.2 197.5%  
Dividends per share (Unadj.) Rs3.002.00 150.0%  
Dividend yield (eoy) %0.50.4 148.9%  
Book value per share (Unadj.) Rs176.7158.8 111.3%  
Shares outstanding (eoy) m805.122,399.26 33.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.05.1 58.8%   
Avg P/E ratio x32.551.6 62.8%  
P/CF ratio (eoy) x16.832.9 51.0%  
Price / Book Value ratio x3.23.6 90.5%  
Dividend payout %17.118.2 93.6%   
Avg Mkt Cap Rs m459,7241,360,021 33.8%   
No. of employees `00023.617.8 132.7%   
Total wages/salary Rs m26,90153,671 50.1%   
Avg. sales/employee Rs Th6,446.114,890.9 43.3%   
Avg. wages/employee Rs Th1,139.43,017.1 37.8%   
Avg. net profit/employee Rs Th600.01,480.6 40.5%   
INCOME DATA
Net Sales Rs m152,193264,895 57.5%  
Other income Rs m3,5778,388 42.6%   
Total revenues Rs m155,769273,282 57.0%   
Gross profit Rs m28,26456,081 50.4%  
Depreciation Rs m13,22814,998 88.2%   
Interest Rs m1,1425,176 22.1%   
Profit before tax Rs m17,47044,295 39.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-775-9,505 8.2%   
Tax Rs m2,5018,452 29.6%   
Profit after tax Rs m14,16626,338 53.8%  
Gross profit margin %18.621.2 87.7%  
Effective tax rate %14.319.1 75.0%   
Net profit margin %9.39.9 93.6%  
BALANCE SHEET DATA
Current assets Rs m108,141316,359 34.2%   
Current liabilities Rs m38,322198,643 19.3%   
Net working cap to sales %45.944.4 103.2%  
Current ratio x2.81.6 177.2%  
Inventory Days Days9795 102.3%  
Debtors Days Days74108 69.1%  
Net fixed assets Rs m109,411213,178 51.3%   
Share capital Rs m1,6102,399 67.1%   
"Free" reserves Rs m140,682378,606 37.2%   
Net worth Rs m142,292381,006 37.3%   
Long term debt Rs m36,62117,721 206.7%   
Total assets Rs m228,606643,028 35.6%  
Interest coverage x16.39.6 170.5%   
Debt to equity ratio x0.30 553.3%  
Sales to assets ratio x0.70.4 161.6%   
Return on assets %6.74.9 136.6%  
Return on equity %10.06.9 144.0%  
Return on capital %10.010.0 99.3%  
Exports to sales %32.80-   
Imports to sales %00-   
Exports (fob) Rs m49,883NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,69140,816 126.6%   
Fx outflow Rs m21,03330,143 69.8%   
Net fx Rs m30,65810,673 287.2%   
CASH FLOW
From Operations Rs m14,62839,072 37.4%  
From Investments Rs m-8,540-33,708 25.3%  
From Financial Activity Rs m-3,855-15,393 25.0%  
Net Cashflow Rs m2,431-7,359 -33.0%  

Share Holding

Indian Promoters % 16.0 63.7 25.1%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 5.1 237.8%  
FIIs % 23.7 23.0 103.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 8.3 315.7%  
Shareholders   161,166 133,026 121.2%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   J.B.CHEMICALS  ALEMBIC LTD  IPCA LABS  CADILA HEALTHCARE  SUVEN LIFE  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Firm; Realty & Consumer Durables Stocks Gain(09:30 am)

Asian stocks are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.1% while the Hang Seng is up 0.4%.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)

Oct 4, 2018

Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)

Oct 3, 2018

A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.

Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)

Oct 3, 2018

Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Oct 16, 2018 12:55 PM

TRACK CIPLA

CIPLA - DR. REDDYS LAB COMPARISON

COMPARE CIPLA WITH

MARKET STATS